MPS Egypt

17/02/2026

07/12/2025

24/07/2025

Are you looking for up-to-date information on clinical trials for MPS? 🧪 Whether you're a patient, caregiver, advocate, or healthcare provider, staying informed is a powerful step toward advocacy, care, and hope.

You can explore ongoing studies through several reliable directories:

🔍 UCSF Clinical Trials Directory
👉 https://clinicaltrials.ucsf.edu/mucopolysaccharidosis

🔍 ClinicalTrials.gov (Global registry of government and industry-supported trials)
👉 https://clinicaltrials.gov
Tip: Search for “Mucopolysaccharidosis” or specific types like “MPS I,” “MPS II,” etc.

🔍 EU Clinical Trials Register (For European studies)
👉 https://www.clinicaltrialsregister.eu

Being informed can help you:
✔ Ask the right questions
✔ Understand eligibility and treatment options
✔ Join research that could drive breakthroughs

08/07/2025

A major step forward for the MPS II (Hunter syndrome) community.

Denali Therapeutics has announced that the FDA has accepted its Biologics License Application (BLA) for tividenofusp alfa (DNL310) and granted it Priority Review, with a target action date of January 5, 2026.

This submission is supported by clinical trial data and reflects years of dedication from families, advocates, and researchers working to bring hope to those affected by Hunter syndrome. Denali is also continuing its global Phase 2/3 COMPASS study, advancing efforts beyond the U.S.

The IMPSN welcomes this encouraging progress and stands with the MPS II community as we await next steps in the FDA’s review.

📅 PDUFA Target Date: January 5, 2026
📰 Read the full release here:
👉 https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-fda-acceptance-and-priority-review

#​MPSCommunity

07/07/2025

🚨 BREAKING NEWS 🚨

We’re encouraged to share an important update for our ( ) community:

The FDA has accepted Denali Therapeutics' application for tividenofusp alfa (DNL310), a potential treatment for Hunter syndrome (MPS II). Even more encouraging—the FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026

We will keep you updated as the process continues! In the mean time, you can read the full announcement here: https://ow.ly/JQsO50WlGSr